Related scientific articles (all)

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Authors : Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H
Year : 2011
Journal : Lancet Oncol
Volume : 12(12)
Pages : 1134-42

A rapid, simple, and reproducible method for the isolation of mesenchymal stromal cells from Wharton's jelly without enzymatic treatment.

Authors : De Bruyn C, Najar M, Raicevic G, Meuleman N, Pieters K, Stamatopoulos B, Delforge A, Bron D, Lagneaux L
Year : 2011
Journal : Stem Cells Dev.
Volume : 20
Pages : 3

Diverticulum of the urachus].

Authors : Sérignol J, Emonts P
Year : 2011
Journal : Rev Med Brux
Volume : 32(1)
Pages : 58-9

12th meeting on emergency care and severe complications in the cancer patient].

Authors : Sculier JP
Year : 2011
Journal : Rev Med Brux
Volume : 32(6)
Pages : 547

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.

Authors : Villanueva C, Awada A, Campone M, Machiels JP, Besse T, Magherini E, Dubin F, Semiond D, Pivot X
Year : 2011
Journal : Eur. J. Cancer
Volume : 47(7)
Pages : 1037-45

The Research Ethics Committee at Universidade Federal de Santa Maria: a brief historical review

Authors : Nardin Weis L, Hundertmarck Minato E, Borges Fagundes R, Bins di Napoli R, Emando Silva C, de Campos Velho MTA, Dal Lago L
Year : 2011
Journal : Revista HCPA
Volume : 31(3)
Pages : 372-76

Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.

Authors : Bedard PL, Singhal SK, Ignatiadis M, Bradbury I, Haibe-Kains B, Desmedt C, Loi S, Evans DB, Michiels S, Dixon JM, Miller WR, Piccart-Gebhart M, Sotiriou C
Year : 2011
Journal : Endocr Relat Cancer
Volume : 18(6)
Pages : 721-30

Immunohistochemical study of 40 cases of longitudinal melanonychia.

Authors : Theunis A, Richert B, Sass U, Lateur N, Sales F, André J
Year : 2011
Journal : Am J Dermatopathol
Volume : 33(1)
Pages : 27-34

Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer.

Authors : Awada A, Saliba W, Bozovic-Spasojevic I
Year : 2011
Journal : Drugs Today (Barc)
Volume : 47(5)
Pages : 335-45

Envelhecimento e doença crônica - editorial

Authors : Dal Lago L
Year : 2011
Journal : Revista da AMRIGS, Porto Allegre
Volume : 55(1)
Pages : 5-6p

Multiple-input multiple-output causal strategies for gene selection.

Authors : Bontempi G, Haibe-Kains B, Desmedt C, Sotiriou C, Quackenbush J
Year : 2011
Journal : BMC Bioinformatics
Volume : 12(1)
Pages : 458

Recurrent thyroid cancer: a molecular-based therapeutic breakthrough.

Authors : Lalami Y, Awada A
Year : 2011
Journal : Curr Opin Oncol
Volume : 23(3)
Pages : 235-40

Comparison of manual and automatic segmentation methods for brain structures in the presence of space-occupying lesions: a multi-expert study.

Authors : Deeley MA, Chen A, Datteri R, Noble JH, Cmelak AJ, Donnelly EF, Malcolm AW, Moretti L, Jaboin J, Niermann K, Yang ES, Yu DS, Yei F, Koyama T, Ding GX, Dawant BM
Year : 2011
Journal : Phys Med Biol
Volume : 56(14)
Pages : 4557-77

DNA methylation profiling reveals a predominant immune component in breast cancers.

Authors : Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Defrance M, Michiels S, Volkmar M, Deplus R, Luciani J, Lallemand F, Larsimont D, Toussaint J, Haussy S, Rothé F, Rouas G, Metzger O, Majjaj S, Saini K, Putmans P, Hames G, van Baren N, Coulie PG, Piccart-Gebhart M, Sotiriou C, Fuks F
Year : 2011
Journal : EMBO Mol Med
Volume : 3(12)
Pages : 726-41

Quantitative immunohistochemical fingerprinting of adhesion/growth-regulatory galectins in salivary gland tumours: divergent profiles with diagnostic potential.

Authors : Remmelink M, de Leval L, Decaestecker C, Duray A, Crompot E, Sirtaine N, André S, Kaltner H, Leroy X, Gabius HJ, Saussez S
Year : 2011
Journal : Histopathology
Volume : 58(4)
Pages : 543-56

Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice?

Authors : Piccart-Gebhart M, Viale G, Ellis P, Abramowicz M, Carey L
Year : 2011
Journal : Ecancermedicalscience
Volume : 5(null)
Pages : 217

New development in hormone receptor-positive disease.

Authors : Piccart-Gebhart M
Year : 2011
Journal : Oncologist
Volume : 16 suppl 1
Pages : 40-50

Evaluation of 18FDG PET-CT in the diagnosis of endometriosis: a prospective study.

Authors : Fastrez M, Nogarède C, Tondeur M, Sirtaine N, Rozenberg S
Year : 2011
Journal : Reprod Sci
Volume : 18(6)
Pages : 540-4

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Authors : Bonnefoi H, Piccart-Gebhart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R
Year : 2011
Journal : Lancet Oncol
Volume : 12(6)
Pages : 527-39

A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.

Authors : Mayer EL, Baurain JF, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart-Cussac A
Year : 2011
Journal : Clin Cancer Res
Volume : 17(21)
Pages : 6897-6904